查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1301123

CAR T 細胞治療市場規模、份額和趨勢分析報告：按產品、按適應症、最終用途、按地區、細分市場趨勢，2023-2030年

CAR T-cell Therapy Market Size, Share & Trends Analysis Report by Product (Abecma, Breyanzi), By Disease Indication (Lymphoma, Leukemia, Multiple Myeloma), By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

CAR T 細胞治療市場增長和趨勢

根據Grand View Research, Inc.最新報告，預計2023年至2030年全球CAR T細胞治療市場規模將以23.32%的複合年增長率增長，2030年達到159.7億美元。

CAR T 細胞療法通過利用患者的免疫系統殺死癌細胞，代表了淋巴瘤、多發性骨髓瘤和白血病等血癌治療的範式轉變。新興國家多發性骨髓瘤等癌症患病率的上升正在推動市場發展。產品批准和重點藥物管道形式的強有力的監管支持也進一步增強了該行業。例如，根據美國國家醫學圖書館 2023 年 4 月的公告，世界各地正在開展大約 310 項與 CAR T 細胞相關的研究，涉及早期 I 期、I 期和 II 期。

多家公司已經建立了戰略合作夥伴關係，並且隨著地域擴張，面臨著覆蓋世界各地治療的壓力。因此，公司正在採取策略，擴大在沒有潛在治療方法或無法獲得血液癌症治療的國家的地理足跡。例如，2022年8月31日，Gilead旗下醫療公司Kite宣佈在沙特阿拉伯、巴西和新加坡擴大其CAR T細胞療法。該公司已報告新加坡有超過 1000 例非霍奇金淋巴瘤 (NHL) 病例，沙特阿拉伯已診斷出約 1700 例。同樣，巴西每年發現約 12,000 例非霍奇金淋巴瘤病例。

COVID-19 大流行使得對患者進行 CAR T 細胞治療變得困難，特別是在大流行早期，當時許多醫院和診所都擠滿了 COVID-19 患者。許多醫院不得不推遲或停止選擇性治療，包括 CAR T 細胞治療，為 COVID-19 患者保留資源。此外，CAR T細胞療法還有顯著的副作用，例如細胞因子釋放綜合徵（CRS），它會導致發燒、低血壓和類似COVID-19症狀的器官損傷，從而帶來治療問題。這是正確的。

此外，發展中國家興起的醫院和癌症治療中心也越來越多地引入CAR T細胞。由於具有成本效益和時間效益的癌症治療促進了市場的整體增長，這些中心正在蓬勃發展。例如，2022年8月，墨西哥癌症治療中心免疫治療研究所推出了一項業務，為美國和加拿大的患者提供CAR T細胞。同樣，在以色列，整個過程都是在內部完成的，處理可以在大約10天內完成，從而節省大量成本。

新興國家熟練專業人員的短缺以及與治療相關的高昂費用仍然是市場增長的挑戰。然而，隨著人們對技術先進的 CAR T 細胞療法的認識不斷提高並獲得越來越多的批准，預計將緩解這些挑戰並促進預測期內的市場增長。據美國癌症治療中心稱，截至 2023 年，美國 FDA 已批准六種 CAR T 細胞療法用於治療血癌。

CAR T 細胞治療市場報告亮點

  • 從產品來看，Yescarta (axicabtagene ciloleucel) 細分市場在 2022 年以 43.76% 的份額佔據主導地位。Yescarta 的高吸收率歸因於其強大的性能和改善的複發性 B 細胞大細胞淋巴瘤成年患者的生存率。
  • 從2022年的疾病指徵來看，淋巴瘤所佔比例最大，為57.15%。該領域的高市場滲透率是由於該疾病在全球範圍內的高患病率。此外，市場參與者對去除 CD-19 抗原的強烈產品關注也推動了增長。
  • 按最終用途劃分，醫院業務由於其強大的財務和運營資源，到 2022 年將佔據 56.26% 的多數份額。此外，醫院實驗室由於加快了這一過程而獲得了很高的份額。
  • 2022 年，北美以 66.70% 的份額佔據市場主導地位。所佔比例之大可能是由於患者人數眾多，並且由於快速批准和強大的醫療覆蓋範圍而總體獲得常見和復雜的醫療保健。

目錄

第一章 調查方法和範圍

  • 市場細分和範圍
    • 市場定義
  • 信息採購
    • 市場形成和數據可視化
    • 驗證和發布數據
  • 調查假設
  • 調查方法
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要信息
    • 初步調查
    • 初步調查詳情
  • 信息或數據分析
    • 數據分析模型
  • 市場形成和驗證
  • 型號詳情
    • 產品流向分析
  • 二級信息列表
  • 全球市場：CAGR計算的目的

第二章執行摘要

  • 市場快照
  • 段快照
  • 競爭格局的快照

3. 市場變量、趨勢和範圍

  • 市場譜系展望
    • 母公司市場展望
    • 相關/補充市場展望
  • 市場趨勢和前景
  • 市場動態
    • 市場驅動力分析
    • 市場約束因素分析
  • 營商環境分析
    • SWOT 分析：按因素（政治/法律、經濟/技術）
    • 波特五力分析
    • COVID-19 的影響分析

第四章 CAR T 細胞治療市場：產品估算和趨勢分析

  • 2022 年和 2030 年產品變化分析和市場份額
  • 按產品
  • Abecma（idecabtagene vicleucel）
    • 2018-2030 年全球 Abekuma（Idekbutagen 車輛）市場（百萬美元）
  • Breyanzi (lisocabtagene maraleucel)
    • 全球 Brayange（Lithocabtagen Malaleusel）市場，2018-2030 年（百萬美元）
  • Carvykti（ciltacabtagene autoleucel）
    • 全球 Curvixty (Siltaka Butagen Autoleucel) 市場，2018-2030 年（百萬美元）
  • Kymriah（tisagenlecleucel）
    • 全球 Kymriah (Tisagen Lukrusel) 市場，2018-2030 年（百萬美元）
  • Tecartus（brexucabtagene autoleucel）
    • 全球 Tecartas (Brexcabutagen Autoleucel) 市場，2018-2030 年（百萬美元）
  • Yescarta（axicabtagene ciloleucel）
    • 全球市場 Yescarta (Axica Butagensiloleucer)，2018-2030（百萬美元）
  • 其他
    • 世界其他地區市場，2018-2030（百萬美元）

第五章 CAR T細胞治療市場：適應症估計和趨勢分析

  • 2022 年和 2030 年指示變化分析和市場份額
  • 按疾病
  • 白血病
    • 全球白血病市場，2018-2030（百萬美元）
  • 淋巴瘤
    • 全球淋巴瘤市場，2018-2030（百萬美元）
  • 多發性骨髓瘤
    • 全球多發性骨髓瘤市場，2018-2030（百萬美元）

第六章最終用途業務分析

  • 2022 年和 2030 年的最終用途變化分析和市場份額
  • 按最終用途
  • 醫院
    • 醫院市場，2018-2030（百萬美元）
  • 癌症治療中心
    • 癌症治療市場，2018-2030（百萬美元）

第七章區域業務分析

  • CAR T 細胞治療市場：區域展望
  • 北美
    • 北美 CAR T 細胞療法市場估計和預測，2018-2030 年（百萬美元）
    • 美國
    • 加拿大
  • 歐洲
    • 2018-2030 年歐洲 CAR T 細胞療法市場估計和預測（百萬美元）
    • 德國
    • 英國
  • 亞太地區
    • 2018-2030 年亞太地區 CAR T 細胞治療市場估計和預測（百萬美元）
    • 日本
    • 中國
  • 世界其他地區
    • 2018-2030 年世界其他地區 CAR T 細胞療法市場估計和預測（百萬美元）

第8章 競爭格局

  • 公司分類
  • 戰略規劃
  • 公司簡介/名單
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Gilead Sciences Inc
    • Bluebird Bio Inc
    • Johnson & Johnson Services Inc
    • Merck & Co.
    • Sorrento Therapeutics Inc
    • Sangamo Therapeutics
    • GSK Plc.
    • JW Therapeutics（Shanghai）Co., Ltd.
Product Code: GVR-4-68040-090-4

CAR T-cell Therapy Market Growth & Trends

The global CAR T-cell therapy market size is expected to reach USD 15.97 billion by 2030, expanding at 23.32% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. CAR T-cell therapy presents a paradigm shift in the treatment of blood cancers such as lymphoma, multiple myeloma, and leukemia by utilizing the patient's immune system to terminate cancer cells. The rising prevalence of cancer types such as multiple myeloma in developing countries is driving the market. Rampant regulatory support in the form of product approvals and an intensive product pipeline of drugs further strengthens the industry. For instance, as per the U.S. National Library of Medicine April 2023, around 310 studies pertinent to CAR T-cells are being conducted across early phase I, phase I, and phase II in various parts of the world.

Various players are entering into strategic partnerships along with geographic expansion to necessitate therapy coverage across the world. Thereby, companies are adopting strategies to increase the geographical footprint in countries without access to potential cures or treatments for blood cancers. For instance, on August 31, 2022, Kite, a medical company operating under Gilead announced the expansion of CAR T-cell therapy in regions of Saudi Arabia, Brazil, and Singapore. The company reported an occurrence of 1000 or higher cases of non-Hodgkin lymphoma (NHL) in Singapore, while around 1700 cases of the disease are diagnosed in Saudi Arabia. Similarly, in Brazil, around 12000 cases of NHL are found each year.

The COVID-19 pandemic has made it difficult to administer CAR T-cell therapy to patients, particularly in the early stages of the pandemic when many hospitals and clinics were overwhelmed with COVID-19 patients. Many hospitals had to postpone or cancel elective procedures, including CAR T-cell therapy, to free up resources for COVID-19 patients. In addition, CAR T-cell therapy has significant side effects, including cytokine release syndrome (CRS), which can cause fever, low blood pressure, and organ damage which mimics the symptoms of COVID-19, thereby, curating problems to treat for condition.

Moreover, hospitals and cancer care centers emerging in developing countries are progressing with the adoption of CAR T-cells. These centers thrive as cost and time-efficient cancer treatments allow the market to grow holistically. For instance, in August 2022, Immunotherapy Institute, a cancer treatment center in Mexico began operations to offer CAR T-cells for American and Canadian patients. Similarly, in Israel, the therapy can be expedited in about 10 days owing to the entire process being conducted in-house, with notable cost reductions.

The lack of skilled professionals in emerging nations coupled with the high cost associated with the therapy remain challenges to market growth. However, rising awareness and increasing approvals for technologically advanced CAR T-cell therapy are anticipated to mitigate these challenges and contribute to market growth over the forecast period. According to Cancer Treatment Centers of America, six CAR T-cell therapies were approved by U.S. FDA for the treatment of blood cancers as of 2023.

CAR T-cell Therapy Market Report Highlights

  • By product, the Yescarta (axicabtagene ciloleucel) segment dominated the market with a share of 43.76% in 2022. The high usage of Yescarta can be attributed to strong performance and improved survivability in adults suffering from relapsed B-cell large lymphoma
  • Lymphoma accounted for the largest share of 57.15% in the disease indication segment in 2022. The high penetration of the market segment owes itself to the significant prevalence of the condition across the world. Additionally, the strong product focus by market players to eliminate the CD-19 antigen drives growth
  • By end-use, the hospital segment captured a majority share of 56.26% in 2022 due to the robust presence of fiscal and operational resources. Additionally, in-house labs for hospitals expedite the process faster, helping to gain a strong share
  • North America has shown a dominant position in the market with a 66.70% share in 2022. The primary reason for a sizable share can be attributed to the patient volume and overall access to general and complex healthcare, with speedy approvals and robust medical insurance coverage

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Market definitions
      • 1.1.1.1. Product segment
      • 1.1.1.2. Disease indication segment
      • 1.1.1.3. End-use segment
  • 1.2. Information Procurement
    • 1.2.1. Market formulation & data visualization
    • 1.2.2. Data validation & publishing
  • 1.3. Research Assumptions
  • 1.4. Research Methodology
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
      • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. Global Market: CAGR CalculationObjectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
      • 3.3.1.1. Growing cases of Cancer Malignancies across population
      • 3.3.1.2. Targeted treatment approach mitigates relapsed or refracted blood cancer cases.
      • 3.3.1.3. Robust product pipeline with regulatory approvals across geographies.
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. High drug cost impedes the market growth
      • 3.3.2.2. Side-effects of CAR T-cell therapy
      • 3.3.2.3. Complex Manufacturing and Supply Chain
  • 3.4. Business Environment Analysis
    • 3.4.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.4.2. Porter's Five Forces Analysis
    • 3.4.3. COVID-19 Impact Analysis

Chapter 4. CAR T-cell Therapy Market: Product Estimates & Trend Analysis

  • 4.1. Product Movement Analysis & Market Share, 2022 & 2030
  • 4.2. CAR T-cell Therapy Market Estimates & Forecast, By Product (USD Million)
  • 4.3. Abecma (idecabtagene vicleucel)
    • 4.3.1. Global Abecma (idecabtagene vicleucel) Market, 2018 - 2030 (USD Million)
  • 4.4. Breyanzi (lisocabtagene maraleucel)
    • 4.4.1. Global Breyanzi (lisocabtagene maraleucel) Market, 2018 - 2030 (USD Million)
  • 4.5. Carvykti (ciltacabtagene autoleucel)
    • 4.5.1. Global Carvykti (ciltacabtagene autoleucel) Market, 2018 - 2030 (USD Million)
  • 4.6. Kymriah (tisagenlecleucel)
    • 4.6.1. Global Kymriah (tisagenlecleucel) Market, 2018 - 2030 (USD Million)
  • 4.7. Tecartus (brexucabtagene autoleucel)
    • 4.7.1. Global Tecartus (brexucabtagene autoleucel) Market, 2018 - 2030 (USD Million)
  • 4.8. Yescarta (axicabtagene ciloleucel)
    • 4.8.1. Global Yescarta (axicabtagene ciloleucel) Market, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Global Others Market, 2018 - 2030 (USD Million)

Chapter 5. CAR T-cell Therapy Market: Disease Indication Estimates & Trend Analysis

  • 5.1. Disease Indication Movement Analysis & Market Share, 2022& 2030
  • 5.2. CAR T-cell Therapy Market Estimates & Forecast, By Disease Indication (USD Million)
  • 5.3. Leukemia
    • 5.3.1. Global Leukemia Market, 2018 - 2030 (USD Million)
  • 5.4. Lymphoma
    • 5.4.1. Global Lymphoma Market, 2018 - 2030 (USD Million)
  • 5.5. Multiple Myeloma
    • 5.5.1. Global Multiple Myeloma Market, 2018 - 2030 (USD Million)

Chapter 6. End-use Business Analysis

  • 6.1. End-use Movement Analysis & Market Share, 2022& 2030
  • 6.2. CAR T-cell Therapy Market Estimates & Forecast, By End-use (USD Million)
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 6.4. Cancer Treatment Centers
    • 6.4.1. Cancer Treatment Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. CAR T-cell Therapy Market: Region Outlook
  • 7.2. North America
    • 7.2.1. North America CAR T-cell Therapy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.2.2. The U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Competitive Scenario
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Disease Prevalence
      • 7.2.2.5. U.S. CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Competitive Scenario
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Disease Prevalence
      • 7.2.3.5. Canada CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe CAR T-cell Therapy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Disease Prevalence
      • 7.3.2.5. Germany CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.3.3. UK
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Disease Prevalence
      • 7.3.3.5. UK CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific CAR T-cell Therapy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Disease Prevalence
      • 7.4.2.5. Japan CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Disease Prevalence
      • 7.4.3.5. China CAR T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5. Rest of World
    • 7.5.1. Rest of World CAR T-cell Therapy market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Profiles/Listing
    • 8.3.1. Bristol-Myers Squibb Company
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Novartis AG
      • 8.3.2.1. Overview
      • 8.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
      • 8.3.2.5. Overview
      • 8.3.2.6. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.2.7. Product Benchmarking
      • 8.3.2.8. Strategic Initiatives
    • 8.3.3. Gilead Sciences Inc
      • 8.3.3.1. Overview
      • 8.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Bluebird Bio Inc
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Johnson & Johnson Services Inc
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Merck & Co.
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Sorrento Therapeutics Inc
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Sangamo Therapeutics
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. GSK Plc.
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. JW Therapeutics (Shanghai) Co., Ltd.
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 3 Global CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 4 Global CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 Global CAR T-cell therapy market, by region, 2018 - 2030 (USD Million)
  • Table 6 North America CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 8 North America CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 9 North America CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 10 U.S. CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 11 U.S. CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 12 U.S. CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 13 Canada CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 14 Canada CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 15 Canada CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 Europe CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 17 Europe CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 18 Europe CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 19 Europe CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 Germany CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 21 Germany CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 22 Germany CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 23 UK CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 24 UK CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 25 UK CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 UK CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 27 Rest of Europe CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 28 Rest of Europe CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 29 Rest of Europe CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific CAR T-cell therapy market, by country, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 34 China CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 35 China CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 36 China CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Japan CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 38 Japan CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 39 Japan CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 40 Rest of Asia-Pacific CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 41 Rest of Asia-Pacific CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 42 Rest of Asia-Pacific CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)
  • Table 43 Rest of World CAR T-cell therapy market, by product, 2018 - 2030 (USD Million)
  • Table 44 Rest of World CAR T-cell therapy market, by disease indication, 2018 - 2030 (USD Million)
  • Table 45 Rest of World CAR T-cell therapy market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 CAR T-cell Therapy sequencing market segmentation
  • Fig. 8 Market snapshot, 2022
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 Swot analysis, by factor (political & legal, economic and technological)
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Market penetration & growth prospect mapping, 2022
  • Fig. 15 Global CAR T-cell therapy: product movement analysis
  • Fig. 16 Global CAR T-cell therapy, for Abecma, 2018 - 2030 (USD million)
  • Fig. 17 Global CAR T-cell therapy, for Breyanzi, 2018 - 2030 (USD million)
  • Fig. 18 Global CAR T-cell therapy, for Carvykti, 2018 - 2030 (USD million)
  • Fig. 19 Global CAR T-cell therapy, for Kymriah, 2018 - 2030 (USD million)
  • Fig. 20 Global CAR T-cell therapy, for Tecartus, 2018 - 2030 (USD million)
  • Fig. 21 Global CAR T-cell therapy, for Yescarta, 2018 - 2030 (USD million)
  • Fig. 22 Global CAR T-cell therapy: disease indication movement analysis
  • Fig. 23 Global CAR T-cell therapy, for leukaemia, 2018 - 2030 (USD million)
  • Fig. 24 Global CAR T-cell therapy, for lymphoma, 2018 - 2030 (USD million)
  • Fig. 25 Global CAR T-cell therapy, for multiple myeloma, 2018 - 2030 (USD million)
  • Fig. 26 Global CAR T-cell therapy: end-use movement analysis
  • Fig. 27 Global CAR T-cell therapy, for hospitals, 2018 - 2030 (USD million)
  • Fig. 28 Global CAR T-cell therapy, for cancer treatment centers, 2018 - 2030 (USD million)
  • Fig. 29 Regional marketplace: key takeaways
  • Fig. 30 Regional outlook, 2022 & 2030
  • Fig. 31 Global CAR T-cell therapy: region movement analysis
  • Fig. 32 North America CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 33 U.S. CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 34 Canada CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 35 Europe CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 36 Germany CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 37 UK CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 38 Rest of Europe CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 39 Asia Pacific CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 40 Japan CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 41 China CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 42 Rest of Asia Pacific CAR T-cell therapy, 2018 - 2030 (USD million)
  • Fig. 43 Rest of World CAR T-cell therapy, 2018 - 2030 (USD million)